title: Interruption of HBV intrauterine transmission: a clinical study.
abstract: OBJECTIVE
  To investigate the effect of hepatitis B virus (HBV) specific immunoglobin (HBIG) and lamivudine on HBV intrauterine transmission in HBsAg positive pregnant women.
  
  
  METHODS
  Each subject in the HBIG group (56 cases) was given 200 IU HBIG intramuscularly (im.) every 4 weeks from 28-week (wk) of gestation, while each subject in the lamivudine group (43 cases) received 100 mg lamivudine orally (po.) every day from 28-wk of gestation until the 30(th) day after labor. Subjects in the control group (52 cases) received no specific treatment. Blood specimens were tested for HBsAg, HBeAg, and HBV-DNA in all maternities at 28-wk of gestation, before delivery, and in their newborns 24 hours before the administration of immune prophylaxis.
  
  
  RESULTS
  Reductions of HBV DNA in both treatments were significant (P<0.05). The rate of neonatal intrauterine HBV infection was significantly lower in HBIG group (16.1 %) and lamivudine group (16.3 %) compared with control group (32.7 %) (P<0.05), but there was no significant difference between HBIG group and lamivudine group (P>0.05). No side effects were found in all the pregnant women or their newborns.
  
  
  CONCLUSIONS
  The risk of HBV intrauterine infection can be effectively reduced by administration of HBIG or Lamivudine in the 3(rd) trimester of HBsAg positive pregnant women.
authors.affiliation: Department of Obstetrics and Gynecology, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, China. tigerli777@163.com
authors.forename: Xiao-Mao
authors.initials: XM
authors.lastname: Li
authors.forename: Yue-Bo
authors.initials: YB
authors.lastname: Yang
authors.forename: Hong-Ying
authors.initials: HY
authors.lastname: Hou
authors.forename: Zhong-Jie
authors.initials: ZJ
authors.lastname: Shi
authors.forename: Hui-Min
authors.initials: HM
authors.lastname: Shen
authors.forename: Ben-Qi
authors.initials: BQ
authors.lastname: Teng
authors.forename: Ai-Min
authors.initials: AM
authors.lastname: Li
authors.forename: Min-Feng
authors.initials: MF
authors.lastname: Shi
authors.forename: Ling
authors.initials: L
authors.lastname: Zou
mesh_terms: D000998:Antiviral Agents / Q000008:administration & dosage* / Q000009:adverse effects; D004279:DNA, Viral / Q000032:analysis; D005260:Female; D006509:Hepatitis B / Q000188:drug therapy* / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission; D006514:Hepatitis B Surface Antigens / Q000235:genetics; D006513:Hepatitis B e Antigens / Q000235:genetics; D006801:Humans; D007136:Immunoglobulins / Q000008:administration & dosage* / Q000009:adverse effects; D015994:Incidence; D007231:Infant, Newborn; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D019259:Lamivudine / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens; D006513:Hepatitis B e Antigens; D007136:Immunoglobulins; D019259:Lamivudine; C045213:hepatitis B hyperimmune globulin